NASDAQ:SYRS - Syros Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Syros Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.74 +0.53 (+10.17 %) (As of 04/3/2020 06:18 AM ET) Add Compare Today's Range$5.14Now: $5.74▼$5.7450-Day Range$4.46MA: $6.18▼$7.8752-Week Range$4.26Now: $5.74▼$11.93Volume143,705 shsAverage Volume252,969 shsMarket Capitalization$249.10 millionP/E RatioN/ADividend YieldN/ABeta1.2 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients. It has target discovery, research collaboration, and option agreement with Incyte to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co., Ltd. for the development and commercialization of SY-1425. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SYRS Previous Symbol CUSIPN/A CIK1556263 Webhttp://www.syros.com/ Phone617-744-1340Debt Debt-to-Equity Ratio0.31 Current Ratio4.87 Quick Ratio4.87Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.98 million Price / Sales125.81 Cash FlowN/A Price / Cash FlowN/A Book Value$1.87 per share Price / Book3.07Profitability EPS (Most Recent Fiscal Year)($1.88) Net Income$-75,440,000.00 Net Margins-3,806.16% Return on Equity-86.29% Return on Assets-56.50%Miscellaneous Employees76 Outstanding Shares43,398,000Market Cap$249.10 million Next Earnings Date5/6/2020 (Estimated) OptionableOptionable Receive SYRS News and Ratings via Email Sign-up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SYRS Rates by TradingView Syros Pharmaceuticals (NASDAQ:SYRS) Frequently Asked Questions How has Syros Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Syros Pharmaceuticals' stock was trading at $5.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SYRS shares have increased by 11.5% and is now trading at $5.74. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Syros Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syros Pharmaceuticals in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Syros Pharmaceuticals. When is Syros Pharmaceuticals' next earnings date? Syros Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for Syros Pharmaceuticals. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals Inc (NASDAQ:SYRS) issued its quarterly earnings data on Thursday, March, 5th. The company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.01. The business had revenue of $0.51 million for the quarter, compared to analyst estimates of $0.79 million. Syros Pharmaceuticals had a negative return on equity of 86.29% and a negative net margin of 3,806.16%. View Syros Pharmaceuticals' earnings history. What price target have analysts set for SYRS? 6 Wall Street analysts have issued 12-month price targets for Syros Pharmaceuticals' stock. Their forecasts range from $8.00 to $18.00. On average, they anticipate Syros Pharmaceuticals' stock price to reach $13.60 in the next year. This suggests a possible upside of 136.9% from the stock's current price. View analysts' price targets for Syros Pharmaceuticals. Has Syros Pharmaceuticals been receiving favorable news coverage? News headlines about SYRS stock have been trending very negative this week, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Syros Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutSyros Pharmaceuticals. Are investors shorting Syros Pharmaceuticals? Syros Pharmaceuticals saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,502,900 shares, an increase of 7.9% from the February 27th total of 2,320,000 shares. Based on an average trading volume of 354,000 shares, the short-interest ratio is currently 7.1 days. Approximately 11.6% of the company's stock are sold short. View Syros Pharmaceuticals' Current Options Chain. Who are some of Syros Pharmaceuticals' key competitors? Some companies that are related to Syros Pharmaceuticals include Y-mAbs Therapeutics (YMAB), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX), Heron Therapeutics (HRTX), I-Mab (ARQT), Phibro Animal Health (PAHC), NextCure (NXTC), Madrigal Pharmaceuticals (MDGL), Supernus Pharmaceuticals (SUPN), Amneal Pharmaceuticals (AMRX), Akebia Therapeutics (AKBA), Aimmune Therapeutics (AIMT), Kiniksa Pharmaceuticals (KNSA), Odonate Therapeutics (ODT) and Esperion Therapeutics (ESPR). What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Syros Pharmaceuticals investors own include Corbus Pharmaceuticals (CRBP), Sangamo Therapeutics (SGMO), Amarin (AMRN), Crispr Therapeutics (CRSP), ImmunoGen (IMGN), Zynerba Pharmaceuticals (ZYNE), Abeona Therapeutics (ABEO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR) and Intellia Therapeutics (NTLA). Who are Syros Pharmaceuticals' key executives? Syros Pharmaceuticals' management team includes the following people: Dr. Nancy A. Simonian, Pres, CEO & Director (Age 58)Dr. Richard A. Young, Scientific Founder, Member of Scientific Advisory Board & Director (Age 65)Dr. David A. Roth, Chief Medical Officer (Age 56)Dr. Jeremy P. Springhorn, Chief Bus. Officer (Age 57)Dr. Nathanael S. Gray, Scientific Founder & Member of Scientific Advisory Board When did Syros Pharmaceuticals IPO? (SYRS) raised $60 million in an IPO on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Syros Pharmaceuticals' stock symbol? Syros Pharmaceuticals trades on the NASDAQ under the ticker symbol "SYRS." How do I buy shares of Syros Pharmaceuticals? Shares of SYRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Syros Pharmaceuticals' stock price today? One share of SYRS stock can currently be purchased for approximately $5.74. How big of a company is Syros Pharmaceuticals? Syros Pharmaceuticals has a market capitalization of $249.10 million and generates $1.98 million in revenue each year. The company earns $-75,440,000.00 in net income (profit) each year or ($1.88) on an earnings per share basis. Syros Pharmaceuticals employs 76 workers across the globe. View additional information about Syros Pharmaceuticals. What is Syros Pharmaceuticals' official website? The official website for Syros Pharmaceuticals is http://www.syros.com/. How can I contact Syros Pharmaceuticals? Syros Pharmaceuticals' mailing address is 35 Cambridge Park Drive 4th Floor, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-744-1340 or via email at [email protected] MarketBeat Community Rating for Syros Pharmaceuticals (NASDAQ SYRS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 323 (Vote Outperform)Underperform Votes: 299 (Vote Underperform)Total Votes: 622MarketBeat's community ratings are surveys of what our community members think about Syros Pharmaceuticals and other stocks. Vote "Outperform" if you believe SYRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYRS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/3/2020 by MarketBeat.com StaffFeatured Article: What is the S&P/ASX 200 Index?
